---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035603"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:51:23.710887+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma Q2 net loss narrows to $45.8M; LYL797 shows 40% ORR in TNBC

## Summary
- Net loss of $45.8M ($63.9M in Q2 2023); non-GAAP net loss $39.1M ($45.6M).
- Cash, equivalents and marketable securities $491.1M as of June 30, 2024, funding operations into 2027.
- LYL797 Phase 1: 40% objective response rate and 60% clinical benefit rate at 150x10^6 cells in relapsed/refractory TNBC.
- FDA cleared IND for LYL119 (next-gen ROR1 CAR T); Phase 1 to start in ROR1+ ovarian/endometrial cancers.
- R&D expenses decreased to $40.3M; G&A expenses to $12.3M, driven by November 2023 workforce reduction.

## SEC filing metadata
- accession: 0001628280-24-035603
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828024035603/0001628280-24-035603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828024035603/lyel-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035603
- JSON: https://secwatch.observer/filing/0001628280-24-035603.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.